UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): DECEMBER 10, 2014
Commission File Number: 0-24260
AMEDISYS, INC.
(Exact
Name of Registrant as specified in its Charter)
|
|
|
Delaware |
|
11-3131700 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 7 REGULATION FD
ITEM 7.01. REGULATION FD DISCLOSURE
As of
December 10, 2014, representatives of Amedisys, Inc. (the Company) will begin making presentations at investor conferences using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. The
Company expects to use these slides, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during 2014.
By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that
is required to be disclosed solely by reason of Regulation FD.
The information contained in the slides is summary information that is intended to be
considered in the context of the Companys Securities and Exchange Commission (SEC) filings and other public announcements that it may make, by press release or otherwise, from time to time. The Company undertakes no duty or
obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with
the SEC, through press releases or through other public disclosure.
In accordance with General Instruction B.2 of this Current Report on Form 8-K, the
information presented herein shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, except as previously set forth by specific reference in such a filing.
Use of our Website to Distribute Material Company Information
Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important
information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled
Investors on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the
same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting
them when new information is made available on the Investor Relations subpage of our website.
Certain Forward-Looking Statements
When included in this press release, words like believes, belief, expects, plans, anticipates,
intends, projects, estimates, may, might, would, should and similar expressions are intended to identify forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are
not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with
existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates
and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic
downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet
debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, our ability to comply with requirements
stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on
any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any
changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
2
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
|
|
|
99.1 |
|
Investor Relations Slide Show in use beginning December 10, 2014 (furnished only) |
3
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
AMEDISYS, INC.
(Registrant) |
|
|
By: |
|
/s/ Scott G. Ginn |
|
|
Scott G. Ginn |
|
|
Senior Vice President of Accounting and Controller (Principal Accounting Officer) |
DATE: December 10, 2014
4
Exhibit Index
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Investor Relations Slide Show in use beginning December 10, 2014 (furnished only) |
5
Exhibit 99.1
Amedisys Investor Presentation
December 2014
Amedisys®
Forward-looking Statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are
based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on
forward-looking statements as a prediction of future events.
Additional information regarding factors that could cause actual results to differ materially from
those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031.
We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement
may be based except as required by law.
www.amedisys.com
NASDAQ: AMED
We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press
releases, profiles concerning our business and clinical operations and control processes, and SEC filings.
We intend to use our website to expedite public access
to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information.
Amedisys® 2
Amedisys Snapshot
WASHINGTON
MONTANA
NORTH DAKOTA
MINNESOTA
WISCONSIN
MICHIGAN
OREGON IDAHO WYOMING SOUTH DAKOTA IOWA ILLINOIS INDIANA OHIO PENNSYLVANIA NEW YORK MAINE
CALIFORNIA NEVADA UTAH COLORADO NEBRASKA KANSAS MISSOURI
ARIZONA NEW MEXICO
TEXAS OKLAHOMA ARKANSAS LOUISIANA MISSISSIPPI
ALASKA HAWAII
NEW HAMPSHIRE
VERMONT
MASSACHUSETTS
RHODE ISLAND
CONNECTICUT
NEW JERSEY DELAWARE WASHINGTON, D.C.
MARYLAND WEST VIRGINIA
VIRGINIA KENTUCKY TENNESSEE NORTH CAROLINA SOUTH CAROLINA ALABAMA GEORGIA FLORIDA PUERTO RICO
Amedisys Home Health Care Centers (316 locations)
Amedisys Hospice Care
Centers (80 locations)
Overview
Founded in 1982, publicly listed 1994
396 care centers in 34 states
13,000 employees
55,000 patients currently on census
2013 revenue of $1.2 billion
Amedisys® 3
Business Overview
Business $ (in millions) / % of Revenue Revenue per Visit / Revenue per Day Gross Margin % Reimbursement Type
Home Health
Medicare $185 / 62% $156 45.1% 60-day episode of care
Non-Medicare Episodic $18 / 6% $154 44.4% 60-day episode of care
Non-Medicare Per Visit $34 /
11% $113 24.6% Per visit
Total Home Health $237 / 79%
Hospice $63 / 21% $149
48.1% 96% routine care; daily rate
Total $300 / 100%
Based on 3Q14
financials. Gross margin computed by subtracting cost per visit from revenue per visit in home health and cost per day from hospice revenue per day
Amedisys® 4
Adjusted Summary Financials Quarterly
($ in millions, except per share data) 3Q13(1) 4Q13(2) 1Q14(3) 2Q14(4) 3Q14(1)
Net Revenue
$301 $303 $299 $305 $300
Gross Margin % 41.8% 40.9% 41.0% 43.4% 43.3%
Consolidated G&A Expenses 127 126 126 117 113
EBITDA $9 $8 $5 $22 $24
EBITDA Margin 2.9% 2.5% 1.8% 7.3% 7.9%
EPS ($0.01) ($0.07) ($0.07) $0.25
$0.28
GAAP EPS ($2.89) ($0.30) ($0.39) $0.24 $0.26
1. The financial results
for the three-month periods ended September 30, 2013 and September 30, 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our
Form 8-K filed with the Securities and Exchange Commission on October 29, 2014
2. The financial results for the three-month period ended December 31, 2014 are
adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on March 12, 2014
3. The financial results for the three-month period ended March 31, 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A
reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on May 8, 2014
4.
The financial results for the three-month period ended June 30, 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our Form
8-K filed with the Securities and Exchange Commission on July 30, 2014
Amedisys®
5
Amedisys Turnaround
Portfolio Rationalization
3Q13 3Q14
Summary of Exit Activity # of Locations Annual Revenue per Care Center ($MM) # of Locations Annual Revenue per Care Center ($MM)
Home Health 377 2.5 316 3.0
Hospice 94 2.7 80 3.2
Total 471 2.6 396 3.0
Home Health Gross Margin Improvements
$92.00 44.0%
42.8% 43.0%
42.1%
$88.00 42.0%
40.5% 41.0%
Cost per Visit
$84.00 39.4% 39.5% 40.0%
$80.00 39.0%
38.0%
$76.00 37.0%
Q313 Q413 Q114 Q214 Q314
Adj. Gross Margin
Consolidated G&A Expense Reductions
130
- G&A reduced 11% y/y
125 - $14MM y/y reduction
120
115 127 126 126
110 117
Adjusted G&A Expenses ($MM)
113
105
Q313 Q413 Q114 Q214 Q314
Revenue and EBITDA Margin
325 9.0%
7.9%
320 7.3% 8.0%
315 7.0%
310 6.0%
Revenue ($MM)
305 5.0%
300 4.0%
295 2.9% 2.5%
290 1.8%
3.0%
Adj. EBITDA Margin
285 2.0%
280 1.0%
275 0.0%
Q313 Q413 Q114 Q214 Q314
Amedisys® 6
2015 Focus
Clinical
excellence
First priority is to provide the best quality care for our patients
Focused on measured outcomes, including patient / family satisfaction and likelihood to recommend
Organic growth
Continue to target market share capture in home health for organic growth
Hospice growth will be key as we seek to reverse ADC declines
Incremental
operating efficiency
Incremental efficiencies in cost of revenue and field and corporate G&A
Disciplined capital allocation strategy
Continue to emphasize delevering the balance sheet
Amedisys®
7
Home Health Segment
($ in
millions) 3Q13 (1) 2Q14 (2) 3Q14 (1)
Net Revenue $237 $244 $237
Adj. Gross
Margin % 40.5% 42.8% 42.1%
Key Operating Statistics
Medicare admissions
45,420 43,974 42,839
Revenue per episode $2,822 $2,845 $2,834
Medicare recert
rate 37.1% 37.4% 38.0%
Cost per visit $87.31 $85.08 $85.47
Operating stats
above include some contribution from closed/consolidated care centers
In 3Q14, our same store Medicare admissions growth was 3% and same store Medicare
recertifications were up 5%
1. The financial results for the three-month periods ended September 30, 2013 and September 30, 2014 are adjusted for certain items and
should be considered a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on October 29, 2014
2. The financial results for the three-month period ended June 30, 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of
this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on July 30, 2014
Amedisys®
8
Hospice Segment
($ in
millions) 3Q13 (1) 2Q14 (2) 3Q14 (1)
Net Revenue $64 $61 $63
Adj. Gross
Margin % 46.5% 46.0% 48.0%
Key Operating Statistics
Average daily census
4,917 4,649 4,596
Admissions 4,352 4,350 4,002
Revenue per day $142.52
$145.44 $149.16
Cost per day $75.79 $78.24 $77.38
Operating stats above
include some contribution from closed/consolidated care centers
In 3Q14, our same store average daily census was down 2%
1. The financial results for the three-month periods ended September 30, 2013 and September 30, 2014 are adjusted for certain items and should be considered a non-GAAP financial
measure. A reconciliation of this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on October 29, 2014
2. The financial results for the three-month period ended June 30, 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of
this non-GAAP financial measure is included as Exhibit 99.1 to our Form 8-K filed with the Securities and Exchange Commission on July 30, 2014
Amedisys®
9
Summary Balance Sheet
Assets ($ in MM) 12/31/13 9/30/14
Cash $17 $6
Accounts Receivable, net 111 103
Property and Equipment 159 141
Goodwill 209 206
Other 230 226
Total Assets 726 682
Liabilities and Equity
Other Liabilities $157 $148
Senior Debt 47 46
2nd Lien Term Loan -- 70
DOJ Settlement Reserve 150 35
Equity 372 383
Total Liabilities and Equity 726 682
Total Leverage Ratio 2.9x 2.1x
Days Sales Outstanding 32 31
Amedisys®
10
Contact Information
Dale
Redman
Interim Chief Financial Officer dale.redman@amedisys.com
David
Castille
Managing Director, Finance david.castille@amedisys.com
Amedisys,
Inc.
5959 S. Sherwood Forest Blvd. Baton Rouge, LA 70816 Office: 225.292.2031
Amedisys®
11
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2024 to May 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From May 2023 to May 2024